Clinical Trials
66 trialsPreliminary Assessment of [18F]BL40 in PET/CT Scans
British Columbia Cancer Agency
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Memorial Sloan Kettering Cancer Center
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
Dana-Farber Cancer Institute
Rifaximin in Patients With Monoclonal Gammopathy
Emory University
HEMO-CONNECT
Centre Hospitalier de la côte Basque
Loncastuximab Tesirine in WM
Dana-Farber Cancer Institute
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
CZAR-1
University of Ulm
Ibrutinib + Venetoclax in Untreated WM
Dana-Farber Cancer Institute
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Dana-Farber Cancer Institute
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Dana-Farber Cancer Institute
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
Mayo Clinic
VIWA-1
University of Ulm
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
MPOWER
University of Utah
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Calibr, a division of Scripps Research
A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531
Hackensack Meridian Health
ZEBRA
Massachusetts General Hospital
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
BLOOD-dose
Rigshospitalet, Denmark
Epcoritamab in Previously Treated WM
Beth Israel Deaconess Medical Center
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
M.D. Anderson Cancer Center
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
University of Chicago
Nemtabrutinib, Bortezomib, and Rituximab for WM
Seoul National University Hospital
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Mayo Clinic
PRAME
Fundación Española de Hematología y Hemoterapía
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia
Mayo Clinic
BDH-WM02
Institute of Hematology & Blood Diseases Hospital, China
BDH-WM01
Institute of Hematology & Blood Diseases Hospital, China
BDH-WM03
Institute of Hematology & Blood Diseases Hospital, China
Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia
Institute of Hematology & Blood Diseases Hospital, China
BRAWM
Sunnybrook Health Sciences Centre
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
City of Hope Medical Center
Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.
Fondazione Italiana Linfomi - ETS
Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia
University of Ulm
ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy
Dana-Farber Cancer Institute
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Dana-Farber Cancer Institute
ZBR in WM
Institute of Hematology & Blood Diseases Hospital, China
RV-WM-0426
University Hospital, Lille
Covid-19 Vaccine Responsiveness in MM and Waldenstrom
Massachusetts General Hospital
WAZABI
French Innovative Leukemia Organisation
Watch and Wait or Worry and Wait in Indolent Lymphoma
Seoul National University Hospital
FIL_BIOWM
Fondazione Italiana Linfomi - ETS
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
UNC Lineberger Comprehensive Cancer Center
Q702 for the Treatment of Patients With Hematologic Malignancies
Mayo Clinic